LogicBio Therapeutics ( NASDAQ: LOGC ) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare LogicBio Therapeutics to similar companies based on the strength of its profitability, earnings, valuation, dividends, institutional ownership, risk and analyst recommendations.
Earnings and Valuation
Get LogicBio Therapeutics alerts: This table compares LogicBio Therapeutics and its rivals revenue, earnings per share and valuation.
Gross Revenue Net Income Price/Earnings Ratio LogicBio Therapeutics N/A -$17.62 million -4.13 LogicBio Therapeutics Competitors $897.63 million $190.37 million -1.10 LogicBio Therapeutics’ rivals have higher revenue and earnings than LogicBio Therapeutics. LogicBio Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares LogicBio Therapeutics and its rivals’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets LogicBio Therapeutics N/A N/A N/A LogicBio Therapeutics Competitors -5,144.22% -64.24% -27.96% Insider & Institutional Ownership
56.5% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 43.5% of LogicBio Therapeutics shares are owned by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and recommmendations for LogicBio Therapeutics and its rivals, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LogicBio Therapeutics 0 0 3 0 3.00 LogicBio Therapeutics Competitors 835 2777 6065 261 2.58 LogicBio Therapeutics currently has a consensus target price of $23.33, indicating a potential upside of 85.77%. As a group, “Biological products, except diagnostic” companies have a potential upside of 39.13%. Given LogicBio Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe LogicBio Therapeutics is more favorable than its rivals.
Summary
LogicBio Therapeutics beats its rivals on 8 of the 12 factors compared.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 that is been developed for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. LogicBio Therapeutics, Inc. has a partnership with Children's Medical Research Institute (CMRI) of Australia to develop new viral vectors. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Receive News & Ratings for LogicBio Therapeutics analysts' ratings for LogicBio Therapeutics and related companies daily email newsletter .
